Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Breast Cancer Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5890-D

    Medicare Part B Step Therapy Breast Cancer

    Customize your policy alerts

    Sign up for zing_health Policy 5890-D alerts

    Get alerted when Policy 5890-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred-product selection and prior authorization exceptions for Medicare Part B members requesting specified breast cancer products. It applies the Advanced Biosimilars First step-therapy program, with nonpreferred coverage available when defined clinical exception criteria are met.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Breast Cancer
    Policy CodePolicy 5890-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Phesgo before requesting nonpreferred Perjeta, unless a qualifying clinical exception supports coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare Part BApplicable benefit
    PhesgoPreferred product
    PerjetaNonpreferred product
    365 daysPrior-treatment lookback
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Exception pathways

    Nonpreferred Product Exceptions

    Nonpreferred Product Clinical Exceptions

    Coverage for the nonpreferred product is provided when ANY of the following criteria is met:

    ANY of the following

    • The member has received treatment with the nonpreferred product within the past 365 days.Within the past 365 days
    • The member has experienced a documented intolerable adverse event to the preferred product.

    An adverse event qualifies for the nonpreferred product exception only when it is documented as intolerable and is not an expected adverse event attributed to the preferred product’s active ingredient, as described in the prescribing information.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for Nonpreferred Product

    Prior authorization is required for Perjeta (pertuzumab), the nonpreferred product. Coverage may be approved through clinical exception review when circumstances exclude use of Phesgo, including qualifying prior treatment or intolerance.

    • Applies to all members requesting treatment with the nonpreferred product.
    • The review is in addition to any applicable NCD, LCD, or Medicare Part B utilization management requirements.
    Prior Authorization

    Preferred Product Clinical Review

    Preferred products may still require clinical prior authorization review. Selection of Phesgo does not eliminate applicable clinical review requirements under the plan.

    • Preferred product: Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf).
    Step Therapy

    Preferred Product Required First

    Use Phesgo before Perjeta unless a qualifying clinical exception applies. The step-therapy requirement applies to members requesting breast cancer treatment with the nonpreferred product.

    • Phesgo is preferred on the plan.
    • Perjeta (pertuzumab) is nonpreferred.
    • This requirement is applied in addition to applicable Medicare Part B coverage and utilization management programs.
    Documentation Required

    Clinical Exception Documentation

    Document the clinical exception supporting Perjeta. A qualifying exception may be based on prior use of the nonpreferred product within the past 365 days or a documented intolerable adverse event to Phesgo.

    • For prior nonpreferred treatment, document that the member received Perjeta within the past 365 days.
    • For intolerance, document that the adverse event was intolerable and was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Denial Risk

    Denial Risk Without a Qualifying Exception

    Perjeta may be denied when neither qualifying exception is met. If the member has not received the nonpreferred product within the past 365 days and has no documented qualifying intolerance to Phesgo, the nonpreferred product does not meet the step-therapy exception criteria.

    • Coverage for the nonpreferred product is based on clinical circumstances that exclude use of the preferred product.
    • The plan's clinical review process determines whether an exception can be made.

    Policy Context

    This policy addresses HER2-targeted antibody products used to treat breast cancer under the Medicare Part B benefit. The plan design identifies Phesgo as the preferred product and Perjeta as the nonpreferred product.

    Coverage of the nonpreferred product is available through a clinical exception process when the preferred product cannot be used or the member has received the nonpreferred product within the past 365 days.

    Key Terms

    Step therapy
    DefinitionA process requiring use of a preferred product before coverage of a nonpreferred product, subject to clinical exceptions.
    Preferred productPhesgo is preferred for the HER2-targeted antibody category.
    Nonpreferred productPerjeta is nonpreferred and requires prior authorization when requested.
    Clinical exception
    DefinitionA review of clinical circumstances that may exclude use of the preferred product and support coverage of a nonpreferred product.
    Qualifying circumstancesThe review may consider previous use of a product or other clinical circumstances that exclude use of the preferred product.

    Nonpreferred Product Coverage

    Initial Nonpreferred-Product Coverage

    Coverage for the nonpreferred product is provided when any of the following criteria is met.

    Initial nonpreferred-product exception

    • Prior nonpreferred-product treatment: Member has received treatment with the nonpreferred product in the past 365 days.past 365 days
    • Preferred-product intolerance: Member has had a documented intolerable adverse event to the preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.documented and not expected from the active ingredient

    Preferred and Nonpreferred Products

    ProductPlan roleAuthorization and step-therapy requirements
    PhesgoPreferredUse before requesting Perjeta. A clinical prior authorization review may still be required.
    PerjetaNonpreferredPrior authorization is required. Coverage requires a qualifying clinical exception, such as treatment with Perjeta within the past 365 days or a documented intolerable adverse event to Phesgo that was not an expected active-ingredient adverse event.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Breast Cancer
    Policy CodePolicy 5890-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Phesgo before requesting nonpreferred Perjeta, unless a qualifying clinical exception supports coverage.
    SourceLink
    On This Page
    Nonpreferred Product ExceptionsAuthorization and Documentation RequirementsPolicy ContextKey TermsNonpreferred Product CoveragePreferred and Nonpreferred Products
    Coverage application
    A qualifying clinical exception may support coverage of the nonpreferred product.